您好,欢迎您

2025 WCLC | 中国学者领衔40+项口头报告,再掀肺癌学术浪潮!

07月23日
编译:肿瘤资讯
来源:2025 WCLC大会官网

2025年世界肺癌大会(WCLC)将于9月6-9日在西班牙巴塞罗那举行,旨在为全球肺癌领域的学者、专家、从业人员提供最新临床研究、科学研究成果及广阔的学术交流平台。


近日,WCLC官网已披露部分口头报告(18个Oral专场)、迷你口头报告(11个Mini Oral专场)摘要标题。40余项由中国研究者主导的重要研究成果入选口头报告,在国际盛会唱响中国好声音。【肿瘤资讯】特此整理,以飨读者。

Oral

摘要号:官网暂未显示

Title:Investigating the Association Between Procedure Duration of Coronary Angiography and Intervention and Postoperative Cancer Risk

标题:冠状动脉造影及介入手术时长与术后癌症风险的关联性研究

讲者:Y. Chen(广州医科大学)

摘要号:OA03.01

Title:Multiomic Single Cell Profiling Reveals Novel Evolutionary Trajectories in Lung Carcinogenesis

标题:多组学单细胞分析揭示肺癌发生发展的新演化轨迹


讲者:H. Hong(广东省人民医院)

摘要号:OA03.02

Title:Deciphering Genomic Evolution of Metastatic Organotropism With Large-Scale Paired Primary Lung Cancers and Metastases

标题:基于大规模配对原发-转移灶解析肺癌转移器官倾向的基因组进化


讲者:W-F. Tang(广东省肺癌研究所)

摘要号:OA03.04

Title:TNFSF8-Targeting CpG Peptide Vaccine Reduces ICB Pneumonitis While Boosting Cancer Immunotherapy Efficacy

标题:靶向TNFSF8的CpG肽疫苗在增强癌症免疫治疗疗效的同时降低免疫检查点抑制剂相关肺炎风险


讲者:Z-X. Rong(南方医科大学南方医院)

摘要号:OA04.02

Title:Implementation of Large Language Model and GraphRAG-Assisted Decision Support for Multidisciplinary Team Cancer Care

标题:大语言模型与GraphRAG辅助决策支持在多学科团队癌症治疗中的应用

讲者:S. Chen(成都市第三人民医院)

摘要号:OA05.03

Title:Ablation to Oligo-Residual Sites Plus ICIs Improved Survival of Patients with Advanced NSCLC: Preliminary Results of a Prospective Phase II Trial
标题:消融至寡残留部位联合ICI改善晚期NSCLC患者的生存率:一项前瞻性II期试验的初步结果


讲者:S. Yang(上海市肺科医院)

摘要号:OA05.01

Title:ASTRUM-002: First-Line Serplulimab Plus Chemotherapy With or Without HLX04 in Advanced Nonsquamous Non-Small Cell Lung Cancer

标题:ASTRUM-002:斯鲁利单抗联合化疗±HLX04一线治疗晚期非鳞状非小细胞肺癌


讲者:石远凯(中国医学科学院肿瘤医院)

摘要号:OA06.01

Title:A First-In-Human Phase 1 Study of SHR-4849 (IDE849), a DLL3-Directed Antibody-Drug Conjugate, in Relapsed SCLC

标题:DLL3靶向抗体偶联药物SHR-4849(IDE849)用于复发性小细胞肺癌的首次人体Ⅰ期研究

讲者:L. Wang(山东第一医科大学附属肿瘤医院)

摘要号:OA07.04

Title:Molecular and Early Outcomes of a Randomized Phase II Trial of Primary Tumor Resection Following EGFR TKI in Metastatic NSCLC

标题:一项随机Ⅱ期试验中,转移性非小细胞肺癌患者在EGFR-TKI治疗后原发肿瘤切除的分子特征与早期结局


讲者:P-H. Chen(中国台湾大学医学院附属医院)

摘要号:OA10.02

Title:Bevacizumab Plus Chemotherapy Versus Chemotherapy in Untreated Non-Squamous NSCLC With Brain Metastases: A Randomized, Phase 3 Study

标题:贝伐珠单抗联合化疗对比化疗用于未经治疗的伴脑转移的非鳞状非小细胞肺癌:一项随机Ⅲ期研究


讲者:M. Li(中山大学肿瘤防治中心)

摘要号:OA10.03

Title:Phase I/II Study of Iza-Bren (BL-B01D1) as Monotherapy in Patients With Locally Advanced or Metastatic EGFR Mutated NSCLC

标题:Iza-Bren(BL-B01D1)单药治疗局部晚期或转移性EGFR突变非小细胞肺癌患者的Ⅰ/Ⅱ期研究


讲者:w. fang(中山大学肿瘤防治中心)

摘要号:OA10.04

Title:Phase II Study of Iza-Bren (BL-B01D1) Combo With Osimertinib in EGFR Mutated Locally Advanced or Metastatic NSCLC Patients


标题:Iza-Bren(BL-B01D1)联合奥希替尼治疗EGFR突变局部晚期或转移性非小细胞肺癌患者的Ⅱ期研究

讲者:周斐(上海市东方医院)

摘要号:OA11.04

Title:Validation and Refinement Proposal of the Ninth Edition n Descriptor for Non-Small Cell Lung Cancer Receiving Neoadjuvant Therapy


标题:第九版非小细胞肺癌新辅助治疗n描述符的验证和细化建议


讲者:H. Si(上海市肺科医院)

摘要号:OA13.01

Title:Hypofractionated vs Conventional Fractionated Radiotherapy With Concurrent Chemotherapy for LS-SCLC: A Multi-Center Phase III Trial

标题:大分割放疗与常规分割放疗联合同步化疗治疗局限期小细胞肺癌:一项多中心Ⅲ期试验


讲者:毕楠(中国医学科学院肿瘤医院)

摘要号:OA14.01

Title:Glutamine Metabolic Reprogramming Drives Evolution of Lung Adenocarcinoma

标题:谷氨酰胺代谢重编程推动肺腺癌的进化


讲者:Y. Wang(上海市肺科医院)

摘要号:OA14.02

Title:DCBLD2high Tumor-Derived Retinoic Acid Orchestrates Macrophages to Drive Vascular Immunosuppression and Immunotherapy Resistance

标题:DCBLD2高表达肿瘤源性视黄酸协调巨噬细胞,推动血管免疫抑制和免疫治疗耐药


讲者:S. Li(南方医科大学南方医院)

Mini Oral

摘要号:MA01.02

Title:Prognostic Value of Residual Viable Tumor in Lymph Nodes of Non-Small Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy

标题:非小细胞肺癌患者接受新辅助化疗免疫治疗后淋巴结中残留活肿瘤细胞的预后价值


讲者:T. Han(北京大学人民医院)

摘要号:MA01.05

Title:Tislelizumab Plus Chemotherapy Followed by Surgery or Radiotherapy and Adjuvant Tislelizumab in Unresectable Stage III NSCLC

标题:替雷利珠单抗联合化疗后手术或放疗及辅助替雷利珠单抗治疗在不可切除的Ⅲ期非小细胞肺癌中的应用


讲者:J. Liu(四川大学华西医院)

摘要号:MA01.09

Title:Sequencing of Radiotherapy and Immunotherapy Stratifies Pneumonitis Risk: A Propensity-Matched Multicenter Study

标题:放疗与免疫治疗的序贯治疗可分层肺炎风险:一项倾向匹配多中心研究


讲者:W. Wei(襄阳市中心医院,湖北文理学院附属医院)

摘要号:MA03.04

Title:Comparative Analysis of Circulating Tumor DNA Monitoring Strategies in Advanced NSCLC With MET Exon 14 Skipping Treated With Ensartinib

标题:恩沙替尼治疗MET外显子14跳跃突变的晚期非小细胞肺癌患者循环肿瘤DNA监测策略的比较分析


讲者:夏旸(浙江大学医学院附属第二医院)

摘要号:MA03.06

Title:Intrathecal Pemetrexed for Lung Adenocarcinoma Leptomeningeal Metastasis: A Study on Efficacy and Liquid Proteomics

标题:鞘内培美曲塞治疗肺腺癌软脑膜转移的疗效及液体蛋白质组学研究


讲者:董晓荣(华中科技大学同济医学院附属协和医院)

摘要号:MA03.07

Title:Multi-Omic Analyses of CSF Reveal Genomic Instability and Suppressed Microenvironment After TKI Resistance in Patients With Brain Metastases

标题:脑脊液多组学分析揭示脑转移患者TKI耐药后的基因组不稳定性及微环境抑制


讲者:M. Li(中山大学肿瘤防治中心)

摘要号:MA03.08

Title:Identification of Circulating microRNA Signature for Diagnosis and Prognosis of Checkpoint Inhibitor-Related Pneumonitis

标题:鉴定循环microRNA标志物用于诊断和预测免疫检查点抑制剂相关肺炎


讲者:H. Deng(广州医科大学附属第一医院,广州医科大学)

摘要号:MA03.09

Title:Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive-Stage Small Cell Lung Cancer

标题:一线斯鲁利单抗联合化疗治疗广泛期小细胞肺癌中的微小残留病灶动态监测


讲者: Y. Xu(吉林大学第一医院)

摘要号:MA04.01

Title:No Versus Systematic Mediastinal LN Dissection for GGO-Dominant Lung Adenocarcinoma: A Multicenter, Phase III, Non-Inferiority RCT

标题:对于以磨玻璃样成分为主的肺腺癌,不进行系统性纵隔淋巴结清扫与进行系统性纵隔淋巴结清扫的对比:一项多中心、Ⅲ期、非劣效性随机对照试验

讲者:Y. Zhang(复旦大学附属肿瘤医院)

摘要号:MA04.03

Title:Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I A EGFR Mutated NSCLC With High Risk (APPOINT)

标题:阿美替尼作为辅助治疗在可切除的ⅠA期 EGFR突变非小细胞肺癌高风险患者中的疗效和安全性(APPOINT)

讲者:W. Zhang(上海交通大学附属胸科医院)

摘要号:MA04.07

Title:A Phase 2 Multicenter Umbrella Trial Assessing Tislelizumab ± Anti-TIGIT or Anti-LAG-3 mAb ± Chemotherapy in Resectable NSCLC

标题:替雷利珠单抗±抗TIGIT/LAG-3单抗±化疗用于可切除非小细胞肺癌的II期多中心伞式试验

讲者:P. Zhang(北京肿瘤医院)

摘要号:MA05.02

Title:The Preliminary Results of Taiwan National LDCT Lung Cancer Screening for Smokers and Nonsmokers With a Family History of Lung Cancer

标题:台湾省有肺癌家族史的吸烟和非吸烟人群低剂量CT肺癌筛查初步结果

讲者:P.C. Yang(中国台湾大学医学院)

摘要号:MA05.07

Title:Breathomics for Early Non-Invasive Detection of Lung Cancer: A Propectively Multicenter Study Using TD-GC-MS and Portable Micro-GC

标题:呼吸组学用于肺癌早期无创检测:基于TD-GC-MS与便携式Micro-GC的前瞻性多中心研究

讲者R. Wang(广州医科大学附属第一医院)

摘要号:MA05.09

Title:Precise Diagnosis of Small Malignant Pulmonary Nodules Driven by Peripheral Single-Cell Immune Signatures: A Prospective Multi-Center Study

标题:基于外周血单细胞免疫特征的恶性肺小结节精准诊断:一项前瞻性多中心研究

讲者:夏旸(浙江大学医学院附属第二医院)

摘要号:MA06.04

Title:Improving Preoperative ctDNA Detection in NSCLC Through Mechanistic Profiling and Multiregion-Informed Customization

标题:基于机制分析与多区域信息定制化提升非小细胞肺癌术前ctDNA检出率

讲者:Y. He(北京大学人民医院)

摘要号:MA06.05

Title:Impact of Bronchoalveolar Lavage Combined With mNGS in Patients With Checkpoint Inhibitor Pneumonia: A Prospective Cohort Study

标题:支气管肺泡灌洗联合宏基因组二代测序对免疫检查点抑制剂相关肺炎患者的影响:前瞻性队列研究

讲者:Z. Zhou(南方医科大学南方医院)

摘要号:MA07.08

Title:MFAP4+ Pericytes Promote Tc17-Mediated Pneumonitis Induced by the Combination of Radiotherapy & Immunotherapy

标题:MFAP4+周细胞促进放疗联合免疫治疗诱发的Tc17介导的肺炎

讲者:X. Bai(南方医科大学)

摘要号:MA07.09

Title:Three-Year Survival Update and Biomarker Analysis of Neoadjuvant Chemoimmunotherapy in Potentially Resectable Stage IIIA/IIIB NSCLC

标题:可切除IIIA/IIIB期NSCLC新辅助免疫化疗的3年生存数据更新及生物标志物分析

讲者:K. Ma(吉林大学第一医院)

摘要号:MA08.01

Title:A Multinational Phase 2 Randomized Pivotal Study of Sunvozertinib in Pretreated NSCLC With EGFR Exon 20 Insertion Mutations

标题:舒沃替尼治疗经治EGFR 20号外显子插入突变非小细胞肺癌的国际多中心II期关键性研究


讲者:王孟昭(北京协和医院)

摘要号:MA08.06

Title:Comparison of Asandeutertinib and Osimertinib in EGFR-Mutated NSCLC With Brain Metastases: Interim Analysis of the ESAONA Pivotal Study

标题:Asandeutertinib对比奥希替尼治疗EGFR突变伴脑转移非小细胞肺癌:ESAONA关键研究中期分析

讲者:石远凯(中国医学科学院肿瘤医院)

摘要号:MA09.07

Title:Body Roundness Index and Polygenic Risk Score Improve Lung Cancer Risk Prediction Over Bmi: Prospective Analyses in the UK Biobank

标题:身体圆度指数与多基因风险评分较BMI更能提升肺癌风险预测效能:英国生物样本库前瞻性分析

讲者:W. Li(天津医科大学总医院)

摘要号:MA09.09

Title:Unraveling Ancestry Disparities and Intratumoral Heterogeneity in Non-Small Cell Lung Cancer

标题:揭示非小细胞肺癌种族差异与瘤内异质性


讲者:W. Wang(北京大学人民医院)

摘要号:MA10.01

Title:Phase II Trial Ofserplulimab Plus Bevacizumab and Chemotherapyfortreatment-Naïve Non-Squamous NSCLC With Brain Metastases(SUPER BRAIN)

标题:斯鲁利单抗联合贝伐珠单抗及化疗用于初治非鳞非小细胞肺癌脑转移患者的II期研究(SUPER BRAIN)

讲者: H. Yu(中山大学肿瘤防治中心)

摘要号:MA10.03

Title:Efficacy and Safety of Cadonilimab Plus Pulocimab in NSCLC Patients Who Progressed Following Prior Immunotherapy: A Phase 1b/2 Study

标题:卡度尼利单抗联合Pulocimab治疗免疫治疗进展后NSCLC患者的疗效与安全性:Ib/II期研究

讲者:Y. Zheng(浙江大学医学院附属第一医院)

摘要号:MA11.03

Title:Tifcemalimab Plus Toripalimab and Chemotherapy as a First-Line Therapy in ES-SCLC: A Phase Ib/II Study

标题:Tifcemalimab联合特瑞普利单抗及化疗一线治疗广泛期小细胞肺癌的Ib/II期研究


讲者:李子明(上海市胸科医院)

摘要号:MA11.08

Title:Longitudinal Circulating Tumor DNA Dynamics Predict Therapeutic Efficacy in ES-SCLC Treated With Immunotherapy

标题:纵向循环肿瘤DNA动态监测预测广泛期小细胞肺癌免疫治疗疗效

讲者:苏春霞(同济大学附属上海市肺科医院)

摘要号:MA11.09

Title:Circulating Tumor DNA Refines Consolidation Immunotherapy for Limited-Stage SCLC

标题:循环肿瘤DNA优化局限期小细胞肺癌巩固免疫治疗

讲者:毕楠(中国医学科学院肿瘤医院)

摘要号:MA11.10

Title:IFITM3 Enhances Immunotherapy Sensitivity Through MHC-I Regulation in Small Cell Lung Cancer

标题:IFITM3通过调控MHC-I增强小细胞肺癌免疫治疗敏感性


讲者:X. Liu(同济大学附属上海市肺科医院)




如有错漏之处,敬请留言补充!


参考文献

Home - WCLC 2025

责任编辑:肿瘤资讯-TY
排版编辑:肿瘤资讯-TY

评论
07月26日
贾锋
金乡县人民医院 | 血液肿瘤科
2025WCLC在国际盛会唱响中国好声音。
07月26日
陈清
衢州市柯城区人民医院 | 血液肿瘤科
好好学习天天向上
07月25日
魏植强
三明市第一医院沙县医院 | 肿瘤内科
每日学习一点点,每日进步一点点。